semaglutide microneedle patch (DW-1022) / Raphas, Daewon Pharma - LARVOL DELTA

Pharmacokinetics and Safety of a Semaglutide Microneedle Patch in a First-in-Human Study (OBESITY WEEK 2026) - No abstract available

Clinical • First-in-human • P1 data • PK/PD data

Korean pharma firms vie to develop patch-type obesity drugs (Korea Biomedical Review) - "...Daewoong Therapeutics, an affiliate of the Daewoong Group, plans to apply for an investigational new drug (IND) application for semaglutide-based obesity treatment in the form of a microneedle patch to the Ministry of Food and Drug Safety (MFDS) next year."

Non-US regulatory • Diabetes • Metabolic Disorders • Obesity